NR 546 Week 6 Addiction Medication Table QUESTIONS AND CORRECT DETAILED ANSWERS WITH RATIONALES (VERIFIED ANSWERS) |ALREADY GRADED A+

Drug Name Indication Neurotransmitter(s) Affected Target Symptoms Half-life (T1/2), Metabolism (CYP 450 enzyme) Notable Side Effects (link to NT or affected brain circuit) Initial Dosing Considerations Specific lifespan considerations (age, pregnancy, breastfeeding) Buprenorphine (Subutex) Indication: • Maintenance treatment of opioid dependence • Maintenance treatment of opioid dependence in patients who have achieved and sustainced Half-life: 24-42 hours CYP450: CYP3A4 • Headache, constipation, nausea • Oral hypoesthesia, glossodynia • Orthostatic hypotension • Implant specific: insertion site pain, pruritis, erythema Initial dosing: Day 1: 8 mg Day 2: 12-16 mg Days 3-7: Increase in increments of 4 mg, maximum 32 mg Considerations: • Use with caution in elderly and those with cardiac impairment NR 546 Week 6 Addiction Medication Table QUESTIONS AND CORRECT DETAILED ANSWERS WITH RATIONALES (VERIFIED ANSWERS) |ALREADY GRADED A+ prolonged clinical stability on low-tomoderate doses of a transmucosal buprenorphine containing product • Moderate to severe opioid use disorder in patients who have initiated treatment with a